PMID- 27193415
OWN - NLM
STAT- MEDLINE
DCOM- 20171004
LR  - 20220409
IS  - 1099-1557 (Electronic)
IS  - 1053-8569 (Linking)
VI  - 26
IP  - 1
DP  - 2017 Jan
TI  - Medication-related adverse events during hospitalization: a retrospective patient 
      record review study in The Netherlands.
PG  - 32-39
LID - 10.1002/pds.4037 [doi]
AB  - PURPOSE: Medication-related adverse events (MRAEs) are an important priority for 
      patient safety. Results from Dutch AE studies showed that-despite various 
      improvement initiatives-the incidence of preventable MRAEs did not decline. The 
      aim of this study is to describe the characteristics of MRAEs during 
      hospitalizations using national patient data from records of patients admitted to 
      Dutch hospitals in 2008 and 2011/2012. METHODS: Trained nurses and physicians 
      reviewed the randomly selected records of 8071 patients admitted to one of 20 
      hospitals in 2008 or 2011/2012 during a two-stage review process. Patient and 
      admission characteristics were collected. After identification of a MRAE, 
      physicians determined their potential preventability, drug type, related 
      prescribing factors, and potential consequences. RESULTS: The physicians 
      identified 928 adverse events (AEs) in 857 admissions, of which 218 (15.2%) were 
      medication-related. They judged 55 (18.4%) of these as preventable. 
      Preventability of MRAEs was high in anticoagulant treatment (42.5%). Haematoma 
      (39.0%) and intra-cerebral haemorrhage (25.5%) were common types of 
      anticoagulant-related AEs. Anticoagulant-related AEs were often related to dosage 
      factors (46.9%) and often resulted in an intervention (80.2%), of which 40.2% was 
      judged as preventable. CONCLUSIONS: This study provided detailed information on 
      MRAEs during hospital admissions in The Netherlands. A substantial proportion of 
      AEs was medication-related (15.2%), of which 18.4% was judged to be preventable. 
      As preventability in MRAEs was especially high in anticoagulant treatment 
      (42.5%), those medications are a threat to patient safety. Future research and 
      new safety programs should focus on prevention of AEs related to this medication 
      group. Copyright (c) 2016 John Wiley & Sons, Ltd.
CI  - Copyright (c) 2016 John Wiley & Sons, Ltd.
FAU - Damen, Nikki L
AU  - Damen NL
AD  - Netherlands Institute for Health Services Research (NIVEL), Utrecht, The 
      Netherlands.
FAU - Baines, Rebecca
AU  - Baines R
AD  - Netherlands Institute for Health Services Research (NIVEL), Utrecht, The 
      Netherlands.
FAU - Wagner, Cordula
AU  - Wagner C
AD  - Netherlands Institute for Health Services Research (NIVEL), Utrecht, The 
      Netherlands.
AD  - VU University Medical Center/EMGO+ Institute, Amsterdam, The Netherlands.
FAU - Langelaan, Maaike
AU  - Langelaan M
AD  - Netherlands Institute for Health Services Research (NIVEL), Utrecht, The 
      Netherlands.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160519
PL  - England
TA  - Pharmacoepidemiol Drug Saf
JT  - Pharmacoepidemiology and drug safety
JID - 9208369
RN  - 0 (Anticoagulants)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anticoagulants/administration & dosage/*adverse effects
MH  - Child
MH  - Child, Preschool
MH  - Dose-Response Relationship, Drug
MH  - Drug-Related Side Effects and Adverse Reactions/*epidemiology/prevention & 
      control
MH  - Female
MH  - *Hospitalization
MH  - Humans
MH  - Incidence
MH  - Infant
MH  - Male
MH  - Middle Aged
MH  - Netherlands/epidemiology
MH  - Practice Patterns, Physicians'/*statistics & numerical data
MH  - Retrospective Studies
MH  - Young Adult
OTO - NOTNLM
OT  - adverse events
OT  - anticoagulant treatment
OT  - hospitals
OT  - medication errors
OT  - patient safety
OT  - pharmacoepidemiology
OT  - retrospective studies
EDAT- 2016/05/20 06:00
MHDA- 2017/10/05 06:00
CRDT- 2016/05/20 06:00
PHST- 2016/02/04 00:00 [received]
PHST- 2016/03/22 00:00 [revised]
PHST- 2016/04/30 00:00 [accepted]
PHST- 2016/05/20 06:00 [pubmed]
PHST- 2017/10/05 06:00 [medline]
PHST- 2016/05/20 06:00 [entrez]
AID - 10.1002/pds.4037 [doi]
PST - ppublish
SO  - Pharmacoepidemiol Drug Saf. 2017 Jan;26(1):32-39. doi: 10.1002/pds.4037. Epub 
      2016 May 19.